Spreading SARS {#cesec10}
==============

In the 2003 epidemic of severe acute respiratory syndrome (SARS), most ["superspreading" events](10.1086/512819) happened in hospitals. To find out why, researchers have analysed environmental, administrative, and host risk factors in case wards (where superspreading occurred) and control wards (where patients with SARS were admitted but no nosocomial outbreaks developed) in China. They identified six risk factors for superspreading, including closely spaced beds, staff working with SARS symptoms, and the use of oxygen therapy. The lessons learnt from this study should help to prevent nosocomial outbreaks of other respiratory infections.

BCG vaccine variability... {#cesec20}
==========================

Vaccination of adults with BCG provides variable protection against tuberculosis. One explanation for this variability might be the use of different BCG vaccine strains that were established early or late during the extended culture of attenuated *Mycobacterium bovis*. [A recent analysis](10.1073/pnas.0700869104) of the genome sequence and transcriptome of BCG Pasteur (a late vaccine strain) identifies numerous differences between it and early BCG strains. Because some of these differences are likely to contribute to vaccine immunogenicity, early BCG strains might provide better protection against tuberculosis than the late strains that are currently used in most vaccinations.

...and malaria vaccine choices {#cesec30}
==============================

Antigens included in potential malaria vaccines often contain polymorphisms and it is important to understand the local distribution of these before starting vaccine field trials. [Researchers recently analysed](10.1371/journal.pmed.0040093) polymorphisms in MSP-1~19~ (part of a merozoite surface protein used in one candidate vaccine) in parasites isolated from 100 Malian children. Only 16% of the parasites contained the MSP-1~19~ haplotype included in the candidate vaccine. If immunity elicited by an MSP-1~19~ vaccine is allele specific, this result suggests that a vaccine containing a more common MSP-1~19~ haplotype might work better in this region of Africa.

Complement shutdown {#cesec40}
===================

*Staphylococcus aureus*, like other pathogens, manipulates and evades multiple host immune responses. For example, it evades the human complement system by making the complement inhibitory protein extracellular fibrinogen-binding protein (Efb). Now, [a structure--function study](10.1038/ni1450) shows that the Efb complement-binding domain binds to native C3 (the central component of all three complement pathways) and alters its conformation so that it can no longer participate in the activation of the complement response. Targeting the Efb--C3 interaction might, therefore, provide a new way to combat *S aureus* infections.

Lullaby for sleeping sickness {#cesec50}
=============================

[Researchers have discovered](10.1038/sj.embor.7400930) a new stress-induced signalling pathway in *Trypanosoma brucei* that might provide a therapeutic target for sleeping sickness. They report that depletion of the receptor for the signal-recognition particle (SRP; a ribonucleoprotein complex that is needed to deliver newly made membrane proteins and secreted proteins to the cell surface) kills trypanosomes. Parasite death occurs because SRP accumulates on ribosomes in the absence of its receptor and this silences the production of spliced-leader RNA, which is essential for mRNA production in trypanosomes. This spliced-leader RNA silencing might also occur in related parasites, suggest the researchers.
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Host genetics and infection {#cesec60}
===========================

It is increasingly clear that host genetics affects susceptibility to many infectious diseases. For example, one recent study identified a [second major genetic risk factor](10.1038/ng2000) for early-onset leprosy---the first leprosy susceptibility factor was identified in 2004. The new risk factor---the low-producing lymphotoxin-α (*LTA*) +80 A allele---was associated with increased leprosy risk in a Vietnamese familial study and an Indian case-control study. Analysis of the original Vietnamese family and an additional family also revealed that the low-producing *LTA* +80 AA/AC genotypes increase the risk of leprosy most in people diagnosed before the age of 16 years. [A second study](10.1371/journal.pmed.0040066) investigated the possibility that X-chromosome-linked glucose-6-phosphate dehydrogenase (G6PD) deficiency provides protection against severe malaria. G6PD A--, a mutant G6PD with reduced activity, is widespread in areas of Africa where malaria is endemic. Case-control studies in two ethnic populations in Mali (west Africa) indicate that the uniform G6PD deficiency in the erythrocytes of hemizygous boys but not the mosaic deficiency in the erythrocytes of heterozygous girls provides protection against severe malaria.
